• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press Releases Translations

MSF y DNDi piden más investigación y desarrollo para las enfermedades olvidadas

Ginebra, Suiza / Nueva York, EE. UU. — 23 Feb 2009
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Hace falta más voluntad política para fomentar la innovación médica para millones de personas que sufren enfermedades olvidadas.
[English] [Français] [Português]

La organización médico-humanitaria Médicos Sin Fronteras (MSF) y la Iniciativa de Medicamentos para Enfermedades Olvidadas (DNDi por sus siglas en inglés) pide hoy más Investigación y Desarrollo (I+D) sostenible para abordar enfermedades mortales y olvidadas como la enfermedad del sueño, la leishmaniasis visceral y el Chagas, que afectan a millones de personas en todo el mundo. MSF también anuncia su nuevo apoyo económico y operacional a DNDi, una organización de I+D sin ánimo de lucro cofundada por MSF y cinco institutos de investigación públicos y privados, para responder a la necesidad urgente de nuevos tratamiento y a la falta de liderazgo público en fomentar la I+D y la innovación médica en enfermedades olvidadas.

“Tenemos pacientes que padecen patologías como la enfermedad del sueño que se ven obligados someterse a tratamientos tóxicos y peligrosos para sobrevivir; al mismo tiempo, el tratamiento para las personas con leishmaniasis visceral continúa siendo prohibitivamente caro, y para el Chagas crónico sigue sin haber tratamiento efectivo”, dice el Dr. Christopher Fournier, presidente internacional de MSF. “A través de su trabajo en colaboración, DNDi ha demostrado que una I+D innovadora y orientada a las necesidades puede producir medicamentos adaptados a nuestros pacientes. Sin embargo, DNDi y otros colaboradores públicos y privados no pueden sustituir la voluntad política y el compromiso de los gobiernos para garantizar el acceso de los pacientes a tratamientos vitales para enfermedades olvidadas”.

Desde su creación, DNDi ha desarrollado dos dosis fijas combinadas para la malaria (ASAQ y ASMQ) libres de patentes; medicamentos adaptados a la necesidades de los pacientes y que puede ser producidos por varios fabricantes. De este modo, se asegura la competitividad en los precios y la disponibilidad de los medicamentos. Además, los resultados positivos para mejorar el tratamiento de la enfermedad del sueño, basados en un estudio clínico que DNDi ha acabado recientemente con el apoyo de MSF en el terreno, son prometedores para los enfermos. DNDi también ha desarrollado el portafolio de I+D más grande hasta la fecha para tratamientos potencialmente nuevos para la enfermedad del sueño, la leishmaniasis visceral y el Chagas.

“Para DNDI y sus colaboradores sigue siendo un tremendo desafío estimular la innovación y producir tratamientos efectivos y asequibles para estas enfermedades, que afectan a las poblaciones más pobres del mundo y quedan fuera de los intereses del mercado, por la falta de fondos sostenibles y prevenibles”, dijo Bernard Pécoul, director ejecutivo de DNDi. “Nuestros resultados demuestran que cuando la I+D está guiada por las necesidades de los pacientes, es posible crear recursos médicos punteros accesibles a los pacientes más empobrecidos y vulnerables a las enfermedades olvidadas”.

A pesar de que el panorama global de I+D ha mejorado en el campo de las enfermedades olvidadas desde el 2003, siguen sin estar cubiertas las extremas necesidades de las víctimas que sufren en los países en desarrollo. Un estudio reciente de G-Finder revela que menos de un 5% de toda la I+D mundial para enfermedades olvidadas, está dirigida a patologías como la enfermedad del sueño, la leishmaniasis visceral y el Chagas. Más de 500 millones de personas corren en riesgo de padecer estas tres enfermedades parasitarias. Dada la necesidad de tratamiento de sus pacientes en el terreno, MSF aportará 18 millones de euros a DNDi en los próximos 6 años y continuará dando apoyo sobre el terreno en investigación clínica y operacional para que avance su portafolio.

Notas para editores

Sobre DNDi
La Iniciativa de Medicamentos para Enfermedades Olvidadas (DNDi) es una sociedad independiente, sin ánimo de lucro cuyo objetivo es investigar y desarrollar nuevos y mejorados tratamientos para enfermedades olvidadas como la malaria, la leishmaniasis, la tripanosiomasis humana africana y el Chagas. Para más información: www.dndi.org.

Sobre MSF
Médicos Sin Fronteras (MSF) es una organización médico-humanitaria de carácter internacional creada en 1971. Actualmente, MSF proporciona atención médica de urgencia en unos 60 países a poblaciones en situación precaria y a víctimas de catástrofes de origen natural o humano y de conflictos armados, sin ninguna discriminación por raza, religión o ideología política. MSF utiliza el testimonio para llamar la atención sobre crisis olvidadas. Para más información: www.msf.org.

Contactos para medios

DNDi
Sadia Kaenzig, DNDi Ginebra, +41 (0)79 819 99 71 skaenzig@dndi.org
Michelle French, DNDi Norteamérica, (646) 616-8681 or (646) 552-4600 mfrench@dndi.org

MSF
Michael Goldfarb, MSF USA, +212 763 5783
Michel Peremans, MSF Internacional, +41 (0)79 814 9269
Para imágenes sobre enfermedades olvidadas de la DNDi y MSF, hacer clic en ftp://84.16.88.4/data; usuario: event230208; contraseña: mediadndi o enviar sus peticiones a: Info@dndi.org o llamar a Violaine Dällenbach: 0041 22 906 92 47.

View the 6-minute documentary In the Sleeping Sickness Ward (Banda – Haut Uélé, Democratic Republic of Congo)

Policy advocacy

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo